Shared on 07 Nov 25
Fair value Increased 11%PAHC: Margin Expansion And Business Integration Will Support Performance Amid Moderating Sales
Narrative Update on Phibro Animal Health Analysts have raised their price target for Phibro Animal Health by $4.00 to $39.75. This change is attributed to stronger-than-expected financial guidance, improved profit margins, and continued benefits from recent business integration initiatives.
Shared on 30 Aug 25
Fair value Increased 38%Phibro Animal Health’s analyst price target has been raised to $32.50, reflecting increased confidence in above-consensus FY26 guidance, successful integration of recent acquisitions, and strengthened forward outlook, despite some concerns over the sustainability of growth. Analyst Commentary Strong initial FY26 guidance significantly above Street consensus, indicating improved profit outlook.
Shared on 23 Apr 25
Fair value Decreased 5.26%AnalystConsensusTarget has decreased future PE multiple from 6.3x to 5.4x.
Shared on 17 Apr 25
Fair value Decreased 8.41%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 6.03%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 11 Mar 25
Fair value Decreased 20%AnalystConsensusTarget has decreased revenue growth from 16.1% to 12.4% and increased profit margin from 7.9% to 9.4%.